Why the study?
Evidence on long-term variability and determinants of lipoprotein(a) concentrations remains limited, particularly among Asian populations.
Cohort (n=17,363)
Yes
Lipoprotein(a) concentrations remain generally stable over long-term follow-up, though repeat measurements may be useful for cardiovascular risk stratification in high-risk individuals exhibiting specific predictors such as diabetes or new statin use.
Lipoprotein(a) [Lp(a)] concentrations are mainly determined by genetic factors, yet evidence on their long-term variability and determinants remains limited, particularly among Asian populations. This study examined temporal changes in Lp(a) concentrations and identified clinical predictors of substantial intra-individual elevation. We conducted a retrospective cohort study using the Chang Gung Research Database from January 2004 through December 2019. Adults with baseline and follow-up Lp(a) measurements at least one year apart were included. Participants were categorized according to temporal changes: increase ≥ 10 mg/dL, increase < 10 mg/dL, or decrease. Multivariable logistic regression was used to identify predictors of Lp(a) increase ≥ 10 mg/dL. Among 17,363 participants (mean age 42.1 years; 73.3% male) with a mean follow-up of 5.2 years, median Lp(a) levels declined from 9.3 mg/dL (interquartile range [IQR] 4.1–17.3) to 7.4 mg/dL (IQR 3.6–16.3). Only 479 participants (2.8%) exhibited an increase of ≥ 10 mg/dL. Independent predictors of such elevation included higher baseline Lp(a), new statin initiation, diabetes mellitus, female sex, and higher triglyceride levels. In this large longitudinal Taiwanese cohort, Lp(a) concentrations were generally stable, with only a small proportion showing substantial increases. However, specific clinical factors predicted Lp(a) elevation, suggesting that repeat Lp(a) measurements may be warranted in selected high-risk individuals to enhance cardiovascular risk stratification. Not applicable.
No takes yet. Share an insight, caveat, or question.
Tsai et al. (2026) conducted a cohort in Individuals undergoing routine clinical Lp(a) measurement (n=17,363). Clinical risk factors (including baseline Lp(a), statin initiation, diabetes, female sex, hypertriglyceridemia) vs. Absence of these factors was evaluated on Substantial intra-individual elevation of Lp(a) (increase ≥ 10 mg/dL).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: